Telmisartan Should Not Be Used During Breastfeeding
Telmisartan is contraindicated during breastfeeding and should be avoided—alternative antihypertensive agents that are safe for lactation should be used instead.
Why Telmisartan Is Unsafe for Breastfeeding
The FDA drug label explicitly states that nursing women should not breastfeed during treatment with telmisartan due to potential serious adverse reactions in the breastfed infant, including hypotension, hyperkalemia, and renal impairment 1. While there is no human data on telmisartan presence in breast milk, animal studies show telmisartan concentrations in rat milk at 1.5 to 2 times those found in plasma 1.
All angiotensin receptor blockers (ARBs), including telmisartan, are classified as medications to avoid during lactation according to multiple authoritative guidelines 2. The 2020 Hypertension Canada guidelines specifically list ARBs under "Medications to avoid (Grade C)" for lactation 2.
The European Society of Cardiology guidelines assign ARBs (including telmisartan specifically) an FDA risk category D for breastfeeding, indicating evidence of risk that outweighs potential benefits 3. The JNC 7 guidelines from 2003 explicitly state that "ACEIs and ARBs should be avoided on the basis of reports of adverse fetal and neonatal renal effects" 4.
Safe Alternatives for Breastfeeding Mothers
Instead of telmisartan, first-line antihypertensive agents safe for breastfeeding include:
- Labetalol (Grade D recommendation)
- Methyldopa (Grade D recommendation)
- Long-acting nifedipine (Grade D recommendation)
- Enalapril (Grade D recommendation)
- Captopril (Grade D recommendation)
These agents are recommended by Hypertension Canada 2020 guidelines specifically for lactation 2. The 2025 Circulation guidelines provide additional detail, noting that nifedipine XL has a relative infant dose (RID) of 2.3-3.4%, enalapril 1.1%, and labetalol 3.6%—all well below the 10% safety threshold 5.
Clinical Approach
If a breastfeeding mother is currently on telmisartan:
- Switch immediately to one of the safe alternatives listed above
- Do not continue telmisartan even briefly during breastfeeding
- Prioritize ACE inhibitors (enalapril, captopril) or calcium channel blockers (nifedipine) as first-line alternatives, as these have established safety profiles with low breast milk transfer 2, 5
Important Caveats
While ACE inhibitors are recommended for lactation, there is a theoretical concern about hypotension in premature infants 2. Beta-blockers like labetalol may theoretically cause neonatal bradycardia, so neonatal heart rate monitoring may be warranted 2. However, these theoretical risks are far preferable to the documented serious risks of ARB exposure.
The case report of neonatal acute renal failure following maternal telmisartan exposure 6 underscores the real-world danger of ARB use during the perinatal period, though this case involved pregnancy exposure rather than breastfeeding specifically.